CN101524517A - Chinese and western compound medicine for treating upper respiratory tract infection - Google Patents
Chinese and western compound medicine for treating upper respiratory tract infection Download PDFInfo
- Publication number
- CN101524517A CN101524517A CN200910136082A CN200910136082A CN101524517A CN 101524517 A CN101524517 A CN 101524517A CN 200910136082 A CN200910136082 A CN 200910136082A CN 200910136082 A CN200910136082 A CN 200910136082A CN 101524517 A CN101524517 A CN 101524517A
- Authority
- CN
- China
- Prior art keywords
- milliliters
- medicine
- grams
- cefuroxime
- western
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 11
- 206010046306 Upper respiratory tract infection Diseases 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 title abstract description 8
- 229960001668 cefuroxime Drugs 0.000 claims abstract description 22
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical group N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims abstract description 22
- 241000222336 Ganoderma Species 0.000 claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012267 brine Substances 0.000 claims description 6
- 229940000425 combination drug Drugs 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 6
- 235000014375 Curcuma Nutrition 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 3
- 229920001617 Vinyon Polymers 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- AXONCVPTTFHNOI-UHFFFAOYSA-N kairine Chemical compound C1=CC(O)=C2N(C)CCCC2=C1 AXONCVPTTFHNOI-UHFFFAOYSA-N 0.000 claims description 3
- -1 polyethylene Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 11
- 206010019233 Headaches Diseases 0.000 abstract description 7
- 231100000869 headache Toxicity 0.000 abstract description 7
- 206010011224 Cough Diseases 0.000 abstract description 6
- 208000035143 Bacterial infection Diseases 0.000 abstract description 5
- 241000700605 Viruses Species 0.000 abstract description 5
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 5
- 210000002345 respiratory system Anatomy 0.000 abstract description 5
- 208000036142 Viral infection Diseases 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 230000009385 viral infection Effects 0.000 abstract description 4
- 206010037660 Pyrexia Diseases 0.000 abstract description 2
- 208000033809 Suppuration Diseases 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract 2
- 244000197580 Poria cocos Species 0.000 abstract 2
- 235000008599 Poria cocos Nutrition 0.000 abstract 2
- 208000026435 phlegm Diseases 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 240000002505 Pogostemon cablin Species 0.000 abstract 1
- 235000011751 Pogostemon cablin Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 206010000269 abscess Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 210000002741 palatine tonsil Anatomy 0.000 description 9
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 8
- 230000002146 bilateral effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 4
- 229960002179 ephedrine Drugs 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000158526 Nasalis Species 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000000589 cicatrix Anatomy 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000407170 Curcuma Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010030094 Odynophagia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010039587 Scarlet Fever Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003974 Bacillary infections Diseases 0.000 description 1
- 206010004054 Bacterial upper respiratory tract infections Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010055670 Necrotising ulcerative gingivostomatitis Diseases 0.000 description 1
- 208000006595 Necrotizing Ulcerative Gingivitis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034686 Peritonsillar abscess Diseases 0.000 description 1
- 206010034829 Pharyngeal oedema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000020017 viral respiratory tract infection Diseases 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Chinese and western compound medicine (Xishuyuan) for treating upper respiratory tract infection, which is prepared by mixing Chinese medicine components and western medicine components. The traditional Chinese medicine components comprise radix curcumae, radix rehmanniae recen, herba pogostemonis, lucid ganoderma, fructus aurantii and poria cocos, and the western medicine component is cefuroxime tablets. The contents of the components are as follows: 15 g of traditional Chinese medicine curcuma aromatica, 10 g of dried rehmannia root, 10 g of patchouli, 15 g of lucid ganoderma, 5 g of bitter orange and 5 g of tuckahoe, and 8 tablets of western medicine cefuroxime, wherein each tablet is 0.25 g; forming a prescription. The invention combines modern Chinese and western medicine, and the successfully developed compound medicine is used for treating respiratory tract bacterial infection and viral infection. Can dissolve phlegm, eliminate bacteria or viruses of phlegm and pus generated in human respiratory tract, reduce nasal obstruction, sneeze, throat abscess, pneumonia and cough, and effectively suppress the occurrence probability of headache and fever. Has little side effect, takes effect in 30 minutes and does not hurt the liver, the brain and the kidney.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of upper respiratory tract infection, relate in particular to the medicine of a kind of suitable treatment respiratory bacillary and viral infection.
Background technology
The medicine that is used for the treatment of respiratory tract bacterial infection (nasal obstruction, the glutinous nasal mucus of stream) on the modern medicine has " the desensitization king " of the U.S., and " he decides capsule chlorine ", the traditional Chinese medical science has nose health king drop, the ephedrine drop, and effect is general, does not have the possibility of radical cure.If the treatment viral respiratory tract infection also will add a large amount of antibiotic (amoxicillin, Roxithromycin, acetylspiramycin, cefuroxime, azithromycin etc.), took medicine 6-7 days, just can control disease.Antibiotic rhinorrhea that virus is caused in fact, heating is invalid, they kill and wound all antibacterials in human body, make the immunologic function degression of human body, the course of disease prolongs, and causes other secondary sick generations, as headache, feel sick, cough, diarrhoea, general power etc.
Summary of the invention
Purpose of the present invention is to provide the Chinese and Western combination drug of a kind of determined curative effect, safe ready, dauer effect, treatment upper respiratory tract infection that toxic and side effects is little.
The objective of the invention is to be achieved through the following technical solutions.
A kind of Chinese and Western combination drug for the treatment of upper respiratory tract infection is made up of Chinese medicine ingredients and western medicine composition mixing, and Chinese medicine ingredients comprises Radix Curcumae, Radix Rehmanniae, Herba Pogostemonis, Ganoderma, Fructus Aurantii, Poria, and western medicine composition is the cefuroxime sheet; Described each components contents is respectively: Chinese medicine Radix Curcumae 15 grams, Radix Rehmanniae 10 grams, Herba Pogostemonis 10 grams, Ganoderma 15 grams, Fructus Aurantii 5 grams, Poria 5 grams, totally 8 of every 0.25 grams of Western medicine cefuroxime; Above Chinese medicine and western medicine composition combination forms a prescription.
A kind of Chinese and Western combination drug for the treatment of upper respiratory tract infection, the preparation method of this medicine is as follows:
1) 15 gram Radix Curcumaes, 10 gram Radix Rehmanniae, 10 gram Herba Pogostemonis, 15 kairine sesames are mixed, after cleaning with clear water, after 12 hours, put into marmite, under 50 ℃, boiled 30 minutes with 400 milliliters 20 ℃ water logging bubbles; Pour out 80 milliliters of medicinal liquids wherein then, these 80 milliliters of medicinal liquids by behind the heating evaporation, are concentrated to 20 milliliters of medicinal liquids; Add 5 milliliters of Mel, cool, get 4 milliliters of branches to install to four capacity be in 10 milliliters the vinyon bottle at every turn.
2) get the cefuroxime sheet of 8 0.25 gram/sheets, grind up, the capacity of putting into are 50 milliliters vial.
3) preparation sodium chloride brine: 2.25 gram sodium chloride are dissolved in 250 ml distilled waters, be mixed with the sodium chloride brine of 0.009 grams per milliliter of this concentration, take 30 milliliters, with step 2) in the cefuroxime sheet of grind up shape add, concussion earlier, quiet the putting 20 minutes in back have been made the cefuroxime aqueous solution.
4) with 3) in the preparation the cefuroxime aqueous solution be dosage with per 4 milliliters, be injected into respectively in four polyethylene bottles described in the step 1) with syringe, shook 10 minutes; Room temperature place 7 days standby.
Medicine of the present invention is a kind of Chinese patent medicine for the treatment of upper respiratory tract infection, especially treats upper respiratory tract bacterial infection and viral infection.The present invention combines modern Chinese and western medical science development, have and dissolve sputum and eliminate antibacterial or the virus that in the human respiratory tract, produces sputum and pus, reduced nasal obstruction, sneeze, itching throat, the phenomenon that cough produces, effectively face upward and made headache, the probability that fever diseases occurs.The side effect of this medicine is little, and 30 minutes take effect, can be to liver, and brain, kidney produce injury.
The specific embodiment
At first introduce symptom about viral upper respiratory tract infection.
The common form of expression of viral upper respiratory tract infection has following two kinds: the one, and the common cold type, main morbidity season is many at the beginning of autumn late summer, may persist to spring next year.Symptom is pharyngeal discomfort or pharyngalgia, the watery nasal discharge that continues, and nasal obstruction, sneeze, cough, limb aching pain, weak, headache; Sometimes with in various degree heating.The leukocyte numeration is minimizing or normal more.Multipotency spontaneous recovery in course of disease 3-7 days, but more than also sustainable several weeks.The 2nd, pharyngitis type upper respiratory tract infection, cardinal symptom is a pharyngalgia, and watery nasal discharge is arranged, nasal obstruction, headache, cough and general malaise.Pharynx is red and swollen, and the tonsil lymphocytic hyperplasia can have a little exudate, and mandibular lymph node often has enlargement and tenderness is arranged.The leukocyte numeration is on the low side or normal.Bacterial upper respiratory tract infection is modal infectious disease, and by due to the viruses such as rhinovirus, coronavirus, influenza virus, parainfluenza virus, adenovirus, the course of disease has self limiting mostly.Acute bacterial pharyngitis and tonsillitis patient tonsil have exudate, deradenoncus, and heating companion's surrounding hemogram leukocyte and neutrophilic granulocyte raise and help the clinical diagnosis of bacterial infection.Occurred scarlet fever sample erythra as the patient, or peritonsillar abscess is arranged, then diagnosable is bacterial infection.Acute bacterial pharyngitis and tonsillitic pathogen are mainly A group β Hemolytic streptococcus, and minority is C group or G group β Hemolytic streptococcus.
Radix Curcumae has the effect of soothing the liver promoting QI circulation for relieving depression; Radix Rehmanniae plays the effect of blood circulation promoting and blood stasis dispelling; The property of medicine of Herba Pogostemonis is removing dampness by means of aromatics, delivers loose evil and middle appetizing; Ganoderma, achievement in research have in recent years proved that it has anticancer effect, have antibiosis, suppress cell division, each organ of energy auto-mending human body, and slow down aging, enhancing defending and fighting against diseases ability have multiple curative effect.Mel can be in harmonious proportion the property of medicine, and inlet is lubricated, and heat-clearing and toxic substances removing includes abundant glucose, fructose, aminoacid, mineral, vitamin, various active enzyme, and is nutritious, and the good name of " essences of all sorts of flowers " is arranged.
The instructions of taking of medicine of the present invention is when the patient has respiratory tract disease, and compound medicine of the present invention is directly splashed into (2-4 drips) in the oral cavity, need not cooperate other medicine, after 30 minutes, will feel comfortable.
The present invention is the Chinese and Western hybrid medicine, and Chinese medicine ingredients comprises Radix Curcumae, Radix Rehmanniae, Herba Pogostemonis, Ganoderma, Fructus Aurantii, Poria, and western medicine composition is the cefuroxime sheet; Described each components contents is respectively: Chinese medicine Radix Curcumae 15 grams, Radix Rehmanniae 10 grams, Herba Pogostemonis 10 grams, Ganoderma 15 grams, Fructus Aurantii 5 grams, Poria 5 grams, totally 8 of every 0.25 grams of Western medicine cefuroxime; Above Chinese medicine and western medicine composition combination forms a prescription.
During preparation, at first take by weighing the raw material of corresponding umber: 15 gram Radix Curcumaes, 10 gram Radix Rehmanniae, 10 gram Herba Pogostemonis, 15 kairine sesames are mixed, after cleaning with clear water, after 12 hours, put into marmite, under 50 ℃, boiled 30 minutes with 400 milliliters 20 ℃ water logging bubbles; Pour out 80 milliliters of medicinal liquids wherein then, these 30 milliliters of medicinal liquids by behind the heating evaporation, are concentrated to 20 milliliters of medicinal liquids; Add 5 milliliters of Mel, cool, get 4 milliliters of branches to install to four capacity be in 10 milliliters the vinyon bottle at every turn; Get the cefuroxime sheet of 8 0.25 gram/sheets again, grind up, the capacity of putting into are 50 milliliters vial; Preparation sodium chloride brine: 2.25 gram sodium chloride are dissolved in 250 ml distilled waters, be mixed with the sodium chloride brine of 0.009 grams per milliliter of this concentration, take 30 milliliters, with the hot sheet adding of a full furan of above-mentioned grind up shape, concussion earlier, quiet the putting 20 minutes in back have been made the cefuroxime aqueous solution; Is dosage with the cefuroxime aqueous solution of preparation in above-mentioned with per 4 milliliters, is injected into 1 respectively with syringe) described in four polyethylene bottles in, shook 10 minutes; Room temperature place 7 days standby.
Explanation about Chinese medicine ingredients of the present invention: Radix Curcumae has the effect of soothing the liver promoting QI circulation for relieving depression; Radix Rehmanniae plays the effect of blood circulation promoting and blood stasis dispelling; The property of medicine of Herba Pogostemonis is removing dampness by means of aromatics, delivers loose evil and middle appetizing; Ganoderma, achievement in research have in recent years proved that it has anticancer effect, have antibiosis, suppress cell division, each organ of energy auto-mending human body, and slow down aging, enhancing defending and fighting against diseases ability have multiple curative effect.Mel can be in harmonious proportion the property of medicine, and inlet is lubricated, and heat-clearing and toxic substances removing includes abundant glucose, fructose, aminoacid, mineral, vitamin, various active enzyme, and is nutritious, and the good name of " essences of all sorts of flowers " is arranged.
Explanation about western medicine composition cefuroxime of the present invention: cefuroxime is succeeded in developing by Glaxo Wellcome company at first and is patented, these product at first went on the market in Britain, Ireland and Italy in 1978, commodity are called " Xi Lixin ", and sell many countries and regions in the whole world subsequently.December was examined by U.S. FDA on the 28th in 1987, went on the market in the U.S. in 1988.Because its determined curative effect is so be widely used in resisting the multiple infection that responsive mushroom causes.Its dosage form has dry suspension, tablet, capsule, dispersible tablet and injection etc.
Below referring to concrete case:
(1) People's Hospital, Nanyang, Henan Prov, internal medicine on March 15th, 2009
1. patient male main suit heating, pharyngalgia companion odynophagia 3 days, onset is anxious.
2, have a medical check-up: acute face, body temperature 380C.The oropharynx mucosa is obviously congested, the congested swelling of two palatoglossal arch, both tonsils 11 degree enlargements, the visible point-like purulent secretion in crypts place, pharynx rear wall lymph follicle redness.Can reach a 1.0X2.0cm enlarged lymph node under the right jaw, matter is tough, and the border is clear, activity has tenderness.
3, auxiliary examination: WBC11.1X109/L, neutrophilic granulocyte 85%.Have to infect and exist.
(2) diagnosis and Differential Diagnosis
1. acute suppurative tonsillitis: according to medical history, heating, pharyngalgia and odynophagia; Have a medical check-up both tonsils 11 degree enlargements, the visible point-like purulent secretion in crypts place; Routine blood test, WBC raises, and neutrophilic granulocyte moves to left.Diagnose clear and definite substantially.But still need and the discriminating of following disease.
2.Vincent ' the s angina: this disease General Symptoms is lighter, and pathological changes mostly occurs at a side tonsil, have ulcer easily hemorrhage under the amygdaline pseudomembrane, and tonsillitic pseudomembrane is easily wiped, and does not have wound surface.Pseudomembrane smear Vincent ' s angina can find fusiform bacilarmature and spirillum.
3. the angina that causes of hematopathy: General Symptoms is heavier, and can there be pseudomembrane on the tonsil surface, but ulcer, necrosis are often arranged.The lymph nodes of body as a whole enlargement, blood routine examination, WBC raises unusually, and unusual lymphocyte, mononuclear cell or korocyte are often arranged.
4. scarlet fever: belong to acute infectious disease, often accompany erythra, erathema can appear in oral mucosa, and typical strawberry-like tongue is arranged.
(3) inspection program: the hematuria routine, biochemical complete, infect examination, rabat, electrocardiogram can be done antibacterial in case of necessity and cultivate and susceptibility
(4) treatment plan
With compound medicine of the present invention (popular title: control infection uncommon Shu Yuan): orally administer, every day 2 times.
Oral: 1 of paracetamol-inferior
Symptomatic treatment: with the compound medicine of this kind (uncommon Shu Yuan) treatment pharyngitis.Antipyretic analgesic medicine such as paracetamol
(5) estimate the hospital stays: one week
Patient's progress note:
Xuchang City the People's Hospital, Henan Province internal medicine on March 18th, 2009
1. patient male
Main suit, pharyngeal pain when flowing the cough of clear nasal mucus, paroxysmal sneeze, hyperpyrexia, headache, general power repeatedly.
2, have a medical check-up: the visible nose of health check-up, pharyngeal edema, hyperemia, regional nodes's silght enlargement and tenderness, nasopharynx mucosa chronic congestion,
Two palatoglossal arch hyperemia, both tonsils 11 degree enlargements, the visible cicatrix, uneven in surface, as seen crypts mouth place is dispersed in the cheesy secretions of yellow-white, it can be extruded with spatula extruding palatoglossal arch.Can reach a 1.0X2.0cm enlarged lymph node under the right jaw, matter is tough, and the border is clear, activity has tenderness.
3, auxiliary examination: WBC is normal.
(2) diagnosis and Differential Diagnosis
Acute viral infection:, the outbreak of acute tonsillitis and pharyngitis is arranged according to medical history; Have a medical check-up, two palatoglossal arch hyperemia, both tonsils 11 degree enlargements, the visible cicatrix, uneven in surface, as seen crypts mouth place is dispersed in the cheesy secretions of yellow-white, it can be extruded with spatula extruding palatoglossal arch.Can reach a 1.0X2.0cm enlarged lymph node under the right jaw, matter is tough, and the border is clear, activity has tenderness.Diagnose clear and definite substantially.But still need and the discriminating of following disease.
Keratosis of tonsil: mild symptoms, majority only have the foreign body in pharynx sense.The crypts mouth has yellow-white keratinization thing, and matter is hard, and difficult examination is gone.
(3) inspection program
1. the hematuria routine, infects examination by biochemical complete
2, rabat, electrocardiogram
(4) treatment plan
With compound medicine (uncommon Shu Yuan) control infection.Oral each 3-4 drips, every day 2 times
Antipyretic analgesic: use oral each 2 of ibuprofen, every day 3 times
Estimate the hospital stays: one week
Progress note
Xinxiang City, Henan Province the People's Hospital's internal medicine on March 22nd, 2009
The patient, the man, 36 years old, the main suit took in institute with " the gradual nasal obstruction of bilateral 3 years ".
Occurred bilateral discontinuity before 3 years after the flu, replace the property nasal obstruction,, in headache, epistaxis and tears, be with blood with a small amount of sticking tears.Not good enough through therapeutic effect, and nasal obstruction increases the weight of gradually, and bilateral is persistence.
Whole body is had a medical check-up: still can grow, cardiopulmonary are no abnormal.Blood pressure 110/60mmHg.
Training is checked: ears external auditory meatus is unobstructed, and tympanum is complete, and sign is normal.Nasal membrane chronic congestion, concha nasalis inferior pachymucosa, probe gently press matter hard, do not have depression.The mucomembranous surface injustice is nodositas, and is not good enough to the ephedrine effect, and each nasal meatus of bilateral and olfactory cleft are not seen purulent secretion, and nasal septum does not have obviously bent partially.The paranasal sinus district does not have tenderness.The enlargement of bilateral amygdala I degree, no embolus and cicatrix, a little is dispersed in lymph follicle the pharynx rear wall.Bilateral chamber band, the smooth nothing hyperemia of vocal cords, outreach adduction is all normal.
Auxiliary examination: electrocardiogram: sinus rate.
Diagnosis: chronic hypertrophic rhinitis
Diagnosis basis:
1) patient is cardinal symptom with the nasal obstruction.
2) have a medical check-up: nasal membrane chronic congestion, concha nasalis inferior pachymucosa, probe gently press matter hard, do not have depression.The mucomembranous surface injustice is nodositas, and is not good enough to the ephedrine effect, and each nasal meatus of bilateral and olfactory cleft are not seen purulent secretion, and nasal septum does not have obviously bent partially.
Differential Diagnosis:
1. chronic simple rhinitis: this patient's nasal obstruction is discontinuity, the swelling of concha nasalis inferior mucosa, and probe is gently pressed soft flexible, and is obvious to the ephedrine contractile response.So the chronic simple rhinitis diagnosis is false.
2. allergic rhinitis: this patient also has the symptom of sneeze, flowing water sample tears, rhinocnesmus except the nasal obstruction symptom is arranged, can have clear and definite allergen to bring out.So the diagnosis of allergic rhinitis is false.
Symptomatic treatment is with compound medicine of the present invention (uncommon Shu Yuan), orally administer, the every day-inferior, cured in 15 days.
Claims (2)
1. a Chinese and Western combination drug for the treatment of upper respiratory tract infection is made up of Chinese medicine ingredients and western medicine composition mixing, and it is characterized in that: Chinese medicine ingredients comprises Radix Curcumae, Radix Rehmanniae, Herba Pogostemonis, Ganoderma, Fructus Aurantii, Poria, and western medicine composition is the cefuroxime sheet; Described each components contents is respectively: Chinese medicine Radix Curcumae 15 grams, Radix Rehmanniae 10 grams, Herba Pogostemonis 10 grams, Ganoderma 15 grams, Fructus Aurantii 5 grams, Poria 5 grams, totally 8 of every 0.25 grams of Western medicine cefuroxime; Above Chinese medicine and western medicine composition combination forms a prescription.
2. the Chinese and Western combination drug of treatment upper respiratory tract infection according to claim 1 is characterized in that: the preparation method of this medicine is as follows,
1) 15 gram Radix Curcumaes, 10 gram Radix Rehmanniae, 10 gram Herba Pogostemonis, 15 kairine sesames are mixed, after cleaning with clear water, after 12 hours, put into marmite, under 50 ℃, boiled 30 minutes with 400 milliliters 20 ℃ water logging bubbles; Pour out 80 milliliters of medicinal liquids wherein then, these 80 milliliters of medicinal liquids by behind the heating evaporation, are concentrated to 20 milliliters of medicinal liquids; Add 5 milliliters of Mel, cool, get 4 milliliters of branches to install to four capacity be in 10 milliliters the vinyon bottle at every turn;
2) get the cefuroxime sheet of 8 0.25 gram/sheets, grind up, the capacity of putting into are 50 milliliters vial;
3) preparation sodium chloride brine: 2.25 gram sodium chloride are dissolved in 250 ml distilled waters, be mixed with the sodium chloride brine of 0.009 grams per milliliter of this concentration, take 30 milliliters, 2) in the cefuroxime sheet of grind up shape add, concussion earlier, quiet the putting 20 minutes in back have been made the cefuroxime aqueous solution;
4) with 3) in the preparation the cefuroxime aqueous solution be dosage with per 5 milliliters, be injected into 1 respectively with syringe) described in four polyethylene bottles in, shook 10 minutes; Room temperature place 7 days standby.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910136082A CN101524517A (en) | 2009-04-28 | 2009-04-28 | Chinese and western compound medicine for treating upper respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910136082A CN101524517A (en) | 2009-04-28 | 2009-04-28 | Chinese and western compound medicine for treating upper respiratory tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101524517A true CN101524517A (en) | 2009-09-09 |
Family
ID=41092692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910136082A Pending CN101524517A (en) | 2009-04-28 | 2009-04-28 | Chinese and western compound medicine for treating upper respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101524517A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688444A (en) * | 2012-05-08 | 2012-09-26 | 安徽智远生物科技有限公司 | Chinese traditional medicine for treating upper respiratory tract infection and preparation method thereof |
| WO2013042122A1 (en) | 2011-09-21 | 2013-03-28 | Cohen Irun R | Beta-lactam compounds for enhancing t cell -mediated immune responses |
| CN104958511A (en) * | 2015-07-13 | 2015-10-07 | 刘栋 | Traditional Chinese medicine preparation for treating retropharyngeal abscess and preparation method |
| US9474744B2 (en) | 2011-09-21 | 2016-10-25 | Stem Cell Medicine Ltd. | Beta-lactam compounds for treating diabetes |
| CN112691178A (en) * | 2021-01-29 | 2021-04-23 | 张秋英 | Chinese medicine for treating respiratory system disease and its preparing method |
-
2009
- 2009-04-28 CN CN200910136082A patent/CN101524517A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013042122A1 (en) | 2011-09-21 | 2013-03-28 | Cohen Irun R | Beta-lactam compounds for enhancing t cell -mediated immune responses |
| US9345691B2 (en) | 2011-09-21 | 2016-05-24 | Stem Cell Medicine Ltd. | Beta-lactam compounds for enhancing T cell-mediated immune responses |
| US9474744B2 (en) | 2011-09-21 | 2016-10-25 | Stem Cell Medicine Ltd. | Beta-lactam compounds for treating diabetes |
| CN102688444A (en) * | 2012-05-08 | 2012-09-26 | 安徽智远生物科技有限公司 | Chinese traditional medicine for treating upper respiratory tract infection and preparation method thereof |
| CN102688444B (en) * | 2012-05-08 | 2014-04-09 | 安徽智远生物科技有限公司 | Traditional Chinese medicine for treating upper respiratory tract infection and preparation method thereof |
| CN104958511A (en) * | 2015-07-13 | 2015-10-07 | 刘栋 | Traditional Chinese medicine preparation for treating retropharyngeal abscess and preparation method |
| CN112691178A (en) * | 2021-01-29 | 2021-04-23 | 张秋英 | Chinese medicine for treating respiratory system disease and its preparing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103845642B (en) | A kind of compositions of heat-clearing and toxic substances removing removing heat from blood U.S. face | |
| CN103405596A (en) | Traditional Chinese medicine for treating sinusitis | |
| CN102784282A (en) | Medicine for clearing heat, removing toxicity and reducing fever | |
| CN101524517A (en) | Chinese and western compound medicine for treating upper respiratory tract infection | |
| CN102091250B (en) | Traditional Chinese medicine for treating acute tonsillitis | |
| CN103316086A (en) | Tibetan medicine for treating influenza and preparation method thereof | |
| CN1254254C (en) | Chinese patent drug for treating nasosinusitis | |
| CN103393971B (en) | Traditional Chinese medicine preparation for nursing patients suffering from rhinitis and preparation method thereof | |
| CN102188574B (en) | One treats bronchitic Chinese medicine composition of influenza A virus and preparation method thereof | |
| CN103585360A (en) | Traditional Chinese medicinal preparation for treating upper respiratory tract infection | |
| CN104189605B (en) | Traditional Chinese preparation for treating acute nasopharyngitis and preparation method thereof | |
| CN103585263B (en) | A kind of Chinese medicine composition for the treatment of chronic suppurative otitis media and preparation method thereof | |
| CN106620205A (en) | Externally-used traditional Chinese medicine for foot bath to treat pediatric fever | |
| CN104906440A (en) | Traditional Chinese medicine for acute nasopharyngitis treatment | |
| CN103341146B (en) | Traditional Chinese medicine preparation for treating cold and dampness type chronic rhinitis | |
| CN103656306A (en) | Traditional Chinese medicine for treating urinary tract infection | |
| CN103494986B (en) | The Chinese medicine for the treatment of primary trigeminal neuralgia | |
| CN104474173B (en) | A kind of medicine for treating facioplegia | |
| CN102210765B (en) | Orally-taken Chinese medical decoction for treating lung meridian wind-heat type nasosinusitis | |
| CN100409884C (en) | Chinese traditional medicine for treating cold | |
| CN107050395B (en) | Traditional Chinese medicine sigmoid colon instillation preparation for treating infantile exogenous fever and preparation method and application thereof | |
| CN104906441A (en) | Traditional Chinese medicine for treating damp-heat pouring downward syndrome non-gonococcal urethritis | |
| CN103893509B (en) | A kind of medicine for the treatment of of allergic rhinitis and preparation method | |
| CN105056060A (en) | Medicine for treating chronic nasosinusitis | |
| CN103816318A (en) | Traditional Chinese medicine composition for treating keratitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090909 |